Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales –ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics ...

Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts ...

NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

An acute necrotising myopathy is a distinct form of uncommon muscle disease characterised by the rapid advancement of ...

Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney ...

Experts say everyone over 50 in the UK should be taking a daily pill that slashes cholesterol and blood pressure, and reduces ...

December 31, 2024 -- NAARDEN, the Netherlands and MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical ...

ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the ...

Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million ––Q4 Total Revenue Grew 114% ...

For patients age 50 and older, a statin or statin/ezetimibe combination is recommended for those an eGFR <60 mL/min/1.73 m 2 not treated with chronic dialysis or kidney transplantation ...

High-intensity statin therapy is recommended for all patients with ACS, with the option to start concurrent ezetimibe.

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts ...